tradingkey.logo
tradingkey.logo
Search

BiomX Announces Positive Topline Results From Phase 2 Trial Evaluating Bx211 For The Treatment Of Diabetic Foot Osteomyelitis (DFO)

ReutersMar 31, 2025 10:58 AM
facebooktwitterlinkedin

- Biomx Inc PHGE.A:

  • BIOMX ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 TRIAL EVALUATING BX211 FOR THE TREATMENT OF DIABETIC FOOT OSTEOMYELITIS (DFO)

  • BIOMX INC - BX211 FOUND TO BE SAFE AND WELL-TOLERATED

  • BIOMX INC -PLANNING FOR A PHASE 2/3 TRIAL OF BX211, PENDING U.S. FOOD AND DRUG ADMINISTRATION (FDA) FEEDBACK

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI